FIELD: biotechnology.
SUBSTANCE: invention relates in particular to a CAR-natural killer (NK) cell containing a chimeric antigen receptor (CAR) to BCMA, as well as to a method for its production. A composition for the treatment of BCMA-positive cancer, containing the above CAR natural killer (NK) cell and an excipient are also disclosed.
EFFECT: invention is effective for destruction of BCMA-positive cancer cells.
13 cl, 8 dwg, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED ANTIBODY TO BCMA AND BCMA-CAR-T CELLS | 2020 |
|
RU2762942C1 |
| CHIMERIC ANTIGENIC RECEPTORS TO BCMA | 2015 |
|
RU2747457C2 |
| ANTI-BCMA ANTIBODIES CONTAINING ONLY HEAVY CHAIN | 2017 |
|
RU2781301C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR BCMA AND THEIR USE | 2019 |
|
RU2785658C2 |
| MOLECULES THAT BIND BCMA AND USE OF SUCH MOLECULES | 2019 |
|
RU2812322C2 |
| ANTI-BCMA ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF | 2020 |
|
RU2819660C2 |
| BCMA-TARGETED ANTIBODY AND ITS USE | 2018 |
|
RU2799655C2 |
| HUMANIZED ANTIBODIES AGAINST CD269 (BCMA) | 2015 |
|
RU2749041C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| BCMA HEAVY CHAIN ANTIBODIES | 2018 |
|
RU2816994C2 |
